Trastuzumab Deruxtecan in Participants With HER2-overexpressing Advanced or Metastatic Colorectal Cancer
Completed · Phase 2
Conditions studied: Advanced Colorectal Cancer
In brief
This study will evaluate the efficacy, safety, and pharmacokinetics of Trastuzumab deruxtecan (T-DXd) in participants with human epidermal growth factor 2 (HER2)-overexpressing locally advanced, unresectable, or metastatic colorectal cancer (mCRC).
Key facts
- Study ID
- NCT04744831
- Run by
- Daiichi Sankyo
- People needed
- 122
- Starts
- 2021-03-05
- Expected to finish
- 2024-12-04
- Last updated by the study team
- 2026-01-14
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Norton Cancer Institute Audubon — Louisville, Kentucky, United States
- Massachusetts General Hospital — Boston, Massachusetts, United States
- Dana-Farber Cancer Institute — Boston, Massachusetts, United States
- University of Michigan Health System — Ann Arbor, Michigan, United States
- Memorial Sloan Kettering Cancer Center (MSKCC) — New York, New York, United States
- Duke University Medical Center — Durham, North Carolina, United States
- Sarah Cannon (Tennessee Oncology - Nashville) — Nashville, Tennessee, United States
- The University of Texas MD Anderson Cancer Center — Houston, Texas, United States
- Flinders Medical Centre (FMC) — Bedford Park, Australia
- Blacktown Hospital — Blacktown, Australia
- Royal Brisbane & Women's Hospital — Brisbane, Australia
- Monash Medical Centre — Clayton, Australia
- Peter MacCallum Cancer Centre — Melbourne, Australia
- UCL St-Luc — Brussels, Belgium
- UZ Antwerpen — Edegem, Belgium
- Universitair Ziekenhuis Gent — Ghent, Belgium
- Hopital Jean Minjoz — Besançon, France
- Hopital Edouard Herriot — Lyon, France
- ICM-Val d'Aurelle — Montpellier, France
- University Hospital of nantes — Nantes, France
- Centre Antoine Lacassagne — Nice, France
- Hopital St Antoine — Paris, France
- Centre de Lutte Contre le Cancer CLCC - Institut Curie — Saint-Cloud, France
- Chu Toulouse — Toulouse, France
- The University of Chicago — Chicago, Illinois, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.